IDXX · Earnings call · 2026Q2T · Full report

Geographic Market Commentary

IDEXX LABORATORIES INC /DE · 2026-08-04 · Importance 31 · Surprise 42

Management plans to expand field presence across four international countries during the remainder of 2026, alongside targeted additions in the United States. The strategy is intended to develop veterinary diagnostics adoption and utilization, particularly in markets where wellness testing is less developed than in the U.S. IDEXX is also investing in its global laboratory network, localizing VetConnect PLUS software, and tailoring products such as SNAP 4Dx Leishmania and ProCyte One to regional needs. International markets have delivered multiple quarters of double-digit growth, and approximately 40% of inVue Dx placements are now outside the United States.

Key facts

• IDEXX will expand its field presence across 4 international countries during the remainder of the year, plus targeted additions in the U.S.
• International CAG Diagnostics recurring revenues grew nearly 12% organically in Q2.
• About 40% of inVue Dx placements are coming from international markets.